Top

International Journal of Colorectal Disease

Published in:

01-10-2019 | Colorectal Cancer | Original Article

Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers

Authors: Tsuyoshi Ozawa, Yojiro Hashiguchi, Takahiro Yagi, Yoshihisa Fukushima, Ryu Shimada, Tamuro Hayama, Takeshi Tsuchiya, Keijiro Nozawa, Hisae Iinuma, Soichiro Ishihara, Keiji Matsuda

Published in: International Journal of Colorectal Disease | Issue 10/2019

Abstract

Background

Angiotensin signaling is suggested to be involved in tumorigenesis, tumor proliferation, and metastases. In colorectal cancer (CRC), it was demonstrated that angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) may reduce the risk of CRC; however, their impact on tumor recurrence remains unknown. Therefore, in this study, we evaluated the impact of ACEIs/ARBs on tumor recurrence in CRC patients.

Patients and methods

We retrospectively investigated the clinicopathological data of 461 stage I–III CRC patients. We divided the patients into those who took an ACEI and/or ARB (the ACEI/ARB+ group) and those who did not (the ACEI/ARB− group), and we compared the two groups’ recurrence-free survival (RFS) using a Kaplan-Meier curve analysis and log rank test. We also examined the impact of AGTR1 expression on tumor recurrence, using two public CRC datasets.

Results

The Kaplan-Meier curves showed a trend toward improved RFS in the ACEI/ARB+ group versus the ACEI/ARB− group (p = 0.063). Subgroup analyses demonstrated that the RFS was significantly better in the ACEI/ARB+ group versus the ACEI/ARB− group in the patients with left-sided CRC (p = 0.030) and those with stage I CRC (p = 0.009). Consistent with these findings, the AGTR1 expression was higher in the left-sided versus right-sided colon (p = 0.048). High AGTR1 expression levels were associated with poor RFS in the GSE39582 dataset’s stage I–III CRC patients (p < 0.001), and this finding was also validated in the GSE17536 dataset (p = 0.023).

Conclusion

ACEI/ARB treatment may reduce tumor recurrence in left-sided CRC and early-stage CRC.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRefPubMed

Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5(5):292–302CrossRefPubMed

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027CrossRefPubMed

Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383(9927):1490–1502CrossRefPubMed

Childers WK (2015) Interactions of the renin-angiotensin system in colorectal cancer and metastasis. Int J Color Dis 30(6):749–752CrossRef

Holmes S, Griffith EJ, Musto G, Minuk GY (2013) Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol 37(6):881–885CrossRefPubMed

Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Tsujino T, Tateishi K, Tada M, Omata M, Koike K (2010) Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103(11):1644–1648CrossRefPubMedPubMedCentral

Sun H, Li T, Zhuang R, Cai W, Zheng Y (2017) Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: evidence from a meta-analysis including 55 studies. Medicine (Baltimore) 96(13):e6394CrossRef

Dolley-Hitze T, Jouan F, Martin B, Mottier S, Edeline J, Moranne O, le Pogamp P, Belaud-Rotureau MA, Patard JJ, Rioux-Leclercq N, Vigneau C (2010) Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 103(11):1698–1705CrossRefPubMedPubMedCentral

10.

Ager EI, Wen SW, Chan J, Chong WW, Neo JH, Christophi C (2011) Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation. BMC Cancer 11:274CrossRefPubMedPubMedCentral

11.

Zhou L, Luo Y, Sato S, Tanabe E, Kitayoshi M, Fujiwara R, Sasaki T, Fujii K, Ohmori H, Kuniyasu H (2014) Role of two types of angiotensin II receptors in colorectal carcinoma progression. Pathobiology. 81(4):169–175CrossRefPubMed

12.

Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C (2007) Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 22(4):577–584CrossRefPubMed

13.

Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C (2010) Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 10:134CrossRefPubMedPubMedCentral

14.

Shimizu Y, Amano H, Ito Y, Betto T, Yamane S, Inoue T, Nishizawa N, Matsui Y, Kamata M, Nakamura M, Kitasato H, Koizumi W, Majima M (2017) Angiotensin II subtype 1a receptor signaling in resident hepatic macrophages induces liver metastasis formation. Cancer Sci 108(9):1757–1768CrossRefPubMedPubMedCentral

15.

Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S (2012) Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One 7(12):e50893CrossRefPubMedPubMedCentral

16.

Makar GA, Holmes JH, Yang YX (2014) Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst 106(2):djt374CrossRefPubMedPubMedCentral

17.

Mansouri D, McMillan DC, Roxburgh CS, Crighton EM, Horgan PG (2013) The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. Br J Cancer 109(1):249–256CrossRefPubMedPubMedCentral

18.

Zhou L, Li Y, Hao S, Zhou D, Tan RJ, Nie J, Hou FF, Kahn M, Liu Y (2015) Multiple genes of the renin-angiotensin system are novel targets of Wnt/beta-catenin signaling. J Am Soc Nephrol 26(1):107–120CrossRefPubMed

19.

Marisa L, de Reynies A, Duval A et al (2013) Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 10(5):e1001453CrossRefPubMedPubMedCentral

20.

Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD (2010) Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 138(3):958–968CrossRefPubMed

21.

Petrelli F, Tomasello G, Borgonovo K et al (2016) Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol

22.

Rocken C, Rohl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S, Ebert MPA (2007) The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev 16(6):1206–1212CrossRefPubMed

23.

Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294(2):441–447CrossRefPubMed

24.

Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N (2015) Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol Clin Oncol 3(6):1295–1300CrossRefPubMedPubMedCentral

25.

Cardwell CR, Mc Menamin UC, Hicks BM, Hughes C, Cantwell MM, Murray LJ (2014) Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med 12:28CrossRefPubMedPubMedCentral

26.

Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RMW, Hermans J, Buys CHCM, Plukker JTM (2000) Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes’ C colon cancer. Am J Gastroenterol 95(10):2953–2957CrossRefPubMed

27.

Wen Q, Dunne PD, O'Reilly PG et al (2017) KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. Oncotarget. 8(2):3206–3225CrossRefPubMed

28.

Ahl R, Matthiessen P, Fang X et al (2018) Beta-blockade in rectal Cancer surgery: a simple measure of improving outcomes. Ann Surg

29.

Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, Cai J, Wu Y (2015) Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 64(9):1419–1425CrossRefPubMed

30.

Restivo A, Cocco IM, Casula G et al (2015) Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer. Br J Cancer 113(8):1133–1139CrossRefPubMedPubMedCentral

Title: Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers
Authors: Tsuyoshi Ozawa
Yojiro Hashiguchi
Takahiro Yagi
Yoshihisa Fukushima
Ryu Shimada
Tamuro Hayama
Takeshi Tsuchiya
Keijiro Nozawa
Hisae Iinuma
Soichiro Ishihara
Keiji Matsuda
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: International Journal of Colorectal Disease / Issue 10/2019
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-019-03379-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers

Abstract

Background

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2019

Acute mesenteric ischemia (AMI): absence of renal insufficiency and performance of early bowel resection may indicate improved outcomes

The risk factors for urinary dysfunction after autonomic nerve-preserving rectal cancer surgery: a multicenter retrospective study at Yokohama Clinical Oncology Group (YCOG1307)

Familial and non-familial risk factors associated with colorectal cancer survival in young and middle-aged patients

Post-polypectomy bleeding in hot-snare polypectomy of colonic polyps under continued warfarin or short interruption of direct oral anticoagulants

Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease

A hairy cavity: endoscopic therapy of a presacral recurrence of a complex pilonidal sinus